Cell therapy for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new cell therapy (BGT007H) for people with advanced pancreatic cancer that has not responded to earlier treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You have advanced pancreatic cancer that has not responded to or come back after at least two standard treatments.
- You are generally well enough to be up and about (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within safe limits.
- You are willing to use effective birth control during and for 6 months after the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This early-stage trial tests a new drug called ES502 for patients with advanced cancers (including pancreatic cancer) that have a specific genetic mutation and certain immune markers. The study aims to find the right dose and see if it helps shrink tumors.
This trial tests a new treatment using immune cells (CAR-NK cells) to fight pancreatic cancer that has spread or come back. It may be an option if standard treatments have stopped working, were not tolerated, or were refused.
This trial is testing a new cell therapy called BGT007 for people with advanced pancreatic or colorectal cancer that has not responded to other treatments. The goal is to see if this treatment can shrink tumors or slow the cancer's growth.
This trial tests an experimental cell therapy called MT-601 for people with advanced pancreatic cancer that has not worsened during standard chemotherapy (FOLFIRINOX or nab-paclitaxel/gemcitabine). The goal is to see if this new treatment can help control the cancer.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
Hear when a new Tumor Pancreas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.